The Food and Drug Administration has approved Fresenius Kabi’s Tyenne (tocilizumab-aazg), a biosimilar of Roche Group’s Chugai Seiyaku Kabushiki Kaisha’s Actemra. It is used in the treatment of ...
With this launch, Fresenius Kabi Canada's immunology biosimilar portfolio is further expanding, offering more treatment options for patients with chronic autoimmune conditions Tyenne® is Fresenius ...
Patients treated with TYENNE ® (tocilizumab-aazg) are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive ...
Fresenius Kabi, a part of Fresenius, and a leading provider of essential medicines and medical technologies, announced today that the Centers for Medicare & Medicaid Services has issued ...
The US Food and Drug Administration (FDA) has approved the biosimilar tocilizumab-aazg (Tyenne), Fresenius Kabi, the drug's manufacturer, announced today. This is the second tocilizumab biosimilar ...
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific ...
Fresenius Kabi's tocilizumab biosimilar Tyenne ® is the first and only tocilizumab biosimilar to be launched in Canada and is now commercially available for both subcutaneous and intravenous ...
LAKE ZURICH, Ill., October 29, 2024--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results